Source comparison
CJC-1295 no DAC & Ipamorelin vs Synthetic HGH: Receptor Sensitivity and Feedback Loops
Synthetic human growth hormone (recombinant HGH) administered exogenously creates continuous supraphysiological GH levels. Typically 5–15 ng/mL sustained for 12–18 hours depending on dose and injection timing. This pharmacokinetic profile eliminates interpulse
This comparison does not assign a generated winner or score.
- Synthetic human growth hormone (recombinant HGH) administered exogenously creates continuous supraphysiological GH levels. Typically 5–15 ng/mL sustained for 12–18 hours depending on dose and injection timing. This pharmacokinetic profile eliminates interpulse intervals entirely, overriding the body's feedback mechanisms. Within 14–21 days, GH receptor expression downregulates in liver and skeletal muscle tissue, reducing IGF-1 production per unit of circulating GH. The pituitary responds by suppressing endogenous GH secretion almost completely. A negative feedback response mediated by IGF-1 signaling in the hypothalamus. Clinical data show that stopping exogenous HGH after prolonged use results in a rebound suppression period lasting 2–6 weeks, during which endogenous GH secretion remains below pre-treatment baseline.
- CJC-1295 no DAC & Ipamorelin amplified pulsatile GH release avoids this cascade entirely. Because the peptides clear within 60–90 minutes and interpulse intervals remain intact, somatostatin feedback continues to regulate baseline GH levels. The pituitary never experiences continuous receptor occupancy, so endogenous secretion capacity remains functional. IGF-1 elevation is moderate (20–40% above baseline) rather than supraphysiological (100–300% above baseline with HGH), which means negative feedback to the hypothalamus remains proportional rather than suppressive.
- Peak GH Level
- 10–25 ng/mL
- 5–15 ng/mL sustained 12–18 hours
- 5–15 ng/mL pulsatile
- CJC/Ipamorelin produces higher peaks but shorter duration. Preserves rhythm
- Pulse Duration
- 15–30 minutes
- N/A (continuous)
- 10–20 minutes
- CJC/Ipamorelin matches physiological window; HGH eliminates pulses
- IGF-1 Elevation
- 20–40% above baseline
- 100–300% above baseline
- Baseline reference
- CJC/Ipamorelin stays within physiological range; HGH creates supraphysiological exposure
- Receptor Downregulation
- Minimal to none (maintained pulsatile pattern)
- Significant after 14–21 days
- N/A
- HGH loses efficacy over time; CJC/Ipamorelin maintains receptor sensitivity
- Endogenous GH Suppression
- None (feedback intact)
- Near-complete suppression within 7–14 days
- HGH shuts down natural production; CJC/Ipamorelin amplifies it
- Recovery After Cessation
- Immediate (no rebound suppression)
- 2–6 weeks rebound suppression
- CJC/Ipamorelin can stop anytime; HGH requires tapering or recovery period
- The implications are clearest in research contexts focused on long-term use. Synthetic HGH protocols typically cycle on/off or taper doses to manage receptor desensitization and allow endogenous recovery. CJC-1295 no DAC & Ipamorelin amplified pulsatile GH release requires no cycling because the mechanism preserves rather than replaces natural function. Studies measuring IGF-1 levels after 12–16 weeks of peptide administration show stable elevation without the declining response curve seen with continuous HGH exposure.
- One additional mechanism distinguishes these approaches: growth hormone binding protein (GHBP), a circulating protein that binds free GH and modulates its half-life and receptor availability. Pulsatile GH secretion produces transient saturation of GHBP, allowing free GH to reach target tissues during each pulse. Continuous GH elevation from exogenous HGH saturates GHBP constantly, reducing the proportion of bioavailable GH and shifting pharmacokinetics toward longer half-life and more uniform (but less dynamic) tissue exposure. This is part of why eliminating pulses reduces anabolic signaling even when total GH exposure matches pulsatile protocols. The binding protein kinetics encode additional regulatory information.